Core One Lab News Today

Core One Labs’ Akome Reveals Impressive Results for its Psychedelic ...

Second Ground Breaking Technological AdvancementVANCOUVER, BC / ACCESSWIRE / September 2, 2022 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6)(WKN:A3CSSU) (the "Company" or "Core One")

Press release content from Accesswire. The AP news staff was not involved in its creation.

Core One Labs Inc.: Core One Labs Highlights Key Points from International Investor Call Core One" the " Company") is pleased with the tremendous turnout on the International Investors Call held earlier today. Core Ones Chairman, Dr. Robert E.W. Hancock and Chief Executive Officer, Joel Shacker provided participants an update on the Companys current Intellectual Property and patent application process, cost to produce psilocybin, and the commercial viability. Highlights Intellectual Property an...

Press release content from Accesswire. The AP news staff was not involved in its creation. Core One Labs Highlights Key Points from International Investor Call February 11, 2021 GMT VANCOUVER, BC / ACCESSWIRE / February 10, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (“Core One” the “Company”) is pleased with the tremendous turnout on the International Investors’ Call held earlier today. Core One’s Chairman, Dr. Robert E.W. Hancock and Chief Ex...

(6) VANCOUVER, BC / ACCESSWIRE / February 6, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62)(WKN:A2P8K3) (the "Company") announces that it has engaged Donohoe Advisory Associates LLC ("Donohoe Advisory") in connection with its efforts to seek a listing for its common shares on a NASDAQ Stock Market. The Company expects that listing its common shares on NASDAQ will provide increased investor awareness and market liquidity for shareholders. Donohoe Advisory was founded by Dav...

Core One Labs Inc.: Core One Labs Signs Definitive Agreement for Acquisition of Biosynthetic Psilocybin Research Firm Vocan Biotechnologies Inc. Core One Labs Inc. (CSE:COOL), (OTC:CLABF), (Frankfurt:LD62), (WKN:A14XHT) (the " Company") is pleased to announce that, further to its press release of October 7, 2020, it has entered into a definitive share purchase agreement (the " Purchase Agreement"), dated December 23, 2020, for the acquisition (the " Acquisition") of all of the outstanding share...

Vocan's mission is to use science and proprietary technology to advance the knowledge of natural-based medicines for the treatment of mental health illnesses, and addictions. Vocan's team of scientists, specializing in protein expression and biosynthetic fermentation, have discovered a patentable method of producing psilocybin, the active ingredient in psychotropic mushrooms. This technology will enable the production of GMP (good manufacturing practices) API-grade psilocybin, wh...